Regeneron Pharmaceuticals, Inc. (REGN) News
Follow Regeneron Pharmaceuticals, Inc. (REGN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 63 public stories across 35 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Regeneron Pharmaceuticals Announces Dividend of R$ 0.0574499620 Per Unit
EQUITY | Nov 03, 2026, 08:20 PM UTC
M
Regeneron Reports Fiscal Q3 Profit and EPS
Regeneron reported fiscal 2026 third-quarter profit attributable to shareholders, up 8.54% year over year, and basic EPS.
EQUITY | Nov 02, 2026, 03:58 AM UTC
H
Regeneron Shares Rise 11.5% After Third-Quarter Revenue and EPS Increase
Regeneron reported third-quarter 2026 revenue of $5.1 billion, up 36%, and non-GAAP diluted EPS of $20.07, up 70%.
EARNINGS | Oct 30, 2026, 05:24 PM UTC
M
Regeneron shares rise 11.3% to nearly two-year high after quarterly results exceed expectations
Regeneron shares rose 11.3% to 91, reaching a nearly two-year high after quarterly results exceeded expectations.
EQUITY | Oct 30, 2026, 02:51 PM UTC
M
Regeneron Hits 52-Week Highs as Q3 Adjusted EPS Jumps 70%
Regeneron’s Q3 adjusted EPS surged 70% to $20.07, topping estimates, as Dupixent growth and improved collaboration economics supported results.
EARNINGS | Oct 30, 2026, 02:35 PM UTC
H
Regeneron Third-Quarter Revenue Climbs 36% to $5.12 Billion
Regeneron said third-quarter revenue rose on record sales for three drugs, led by Dupixent. Analysts polled by FactSet expected revenue of $4.56 billion.
EARNINGS | Oct 30, 2026, 02:05 PM UTC
M
Regeneron Shares Rise More Than 8% Premarket After Q3 Earnings Beat
Regeneron reported stronger-than-expected third-quarter earnings, supported by demand for its eye treatments and higher collaboration revenue from Sanofi. Shares gained more than 8% in premarket trading.
EQUITY | Oct 30, 2026, 12:31 PM UTC
M
Regeneron Reports Q3 EPS of $20.07, $3.65 Above Expectations
Regeneron reported Q3 earnings of $20.07 per share, excluding non-recurring items, $3.65 better than expectations. Revenue also beat, according to the headline.
EARNINGS | Oct 30, 2026, 10:34 AM UTC
H
Regeneron Reports Third-Quarter EPS of $18.45
EARNINGS | Oct 30, 2026, 10:30 AM UTC
M
Sanofi Signals Openness to Larger Deals, Raises 2026 Growth Targets
Sanofi signaled an appetite for larger deals and raised its growth targets for 2026 under new CEO Garijo.
EARNINGS | Oct 30, 2026, 10:18 AM UTC
M
Regeneron Q3'26 Earnings Preview: EPS Estimate 16.42 USD
Regeneron is scheduled to report Q3'26 results on October 30 before the market opens. Revenue is estimated at 4.56 billion USD, with EPS at 16.42 USD.
EQUITY | Oct 29, 2026, 11:00 AM UTC
M
Regeneron extends US agreement to increase Ebola treatment supply
Regeneron said it extended an agreement with US health authorities to provide more Ebola treatment drugs amid the ongoing outbreak in Africa.
EQUITY | Oct 26, 2026, 11:51 AM UTC
M
Regeneron Extends BARDA Ebola Treatment Supply Deal by About $270 Million
Regeneron extended its Ebola treatment supply deal with BARDA, adding about $270 million.
EQUITY | Oct 26, 2026, 11:37 AM UTC
L
Regeneron Says Libtayo Achieved 37% Reduction in Death Risk at 44 Months
EQUITY | Oct 25, 2026, 09:18 AM UTC
M
Regeneron Q3'26 earnings preview lists revenue estimate
Regeneron is scheduled to report Q3'26 results on October 30 before the market opens. Revenue and EPS estimates are provided.
EQUITY | Oct 23, 2026, 11:00 AM UTC
L
EU Committee Recommends Updated Libtayo Dosing Regimen
The CHMP recommended the updated dosing regimen for Libtayo across all approved cancer types for EU approval.
REGULATION | Oct 16, 2026, 11:00 AM UTC
M
Regeneron Reports No New Abnormal Bone Growth in Extended Trial
Patients showed no new abnormal bone growth in an extended Phase 3 trial of Regeneron’s recently approved rare disease drug. REGN shares rose about 2.8%, heading for their best day in over a month.
EQUITY | Oct 12, 2026, 05:41 PM UTC
L
Pasatru reports zero new HO lesions in OPTIMA extension
Regeneron said adult FOP patients in the OPTIMA trial extension had zero new heterotopic ossification lesions.
EQUITY | Oct 12, 2026, 04:06 PM UTC
M
Regeneron Expands Sanofi Antibody Pact for $1B Upfront
Regeneron and Sanofi have amended their collaboration agreement for antibody development. Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in potential milestone payments for co-development and co-commer
EQUITY | Oct 06, 2026, 11:53 AM UTC
H
Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment
Sanofi and Regeneron Pharmaceuticals are expanding their immunology alliance, adding four next-generation antibody programs. Regeneron will receive $1 billion upfront and up to $7 billion in potential milestone payments.
EQUITY | Oct 01, 2026, 11:37 AM UTC
H
Sanofi and Regeneron Strike $7 Billion Deal for New Treatments
French drugmaker Sanofi has entered into a $7 billion agreement with Regeneron to develop new treatments. This strategic move aims to replenish Sanofi's drug pipeline as a key existing drug approaches patent expiry. The
MNA | Oct 01, 2026, 09:14 AM UTC
M
Sanofi, Regeneron Expand Alliance in Deal Up to $8 Billion
Drugmakers Sanofi and Regeneron Pharmaceuticals have agreed to expand their alliance as part of a deal valued at up to $8 billion. The companies have also settled prior collaboration-related litigation.
EQUITY | Oct 01, 2026, 05:39 AM UTC
M
Regeneron, Sanofi Expand Alliance With $1B Upfront, $7B Milestones
Regeneron and Sanofi have expanded their antibody alliance to co-develop four long-acting immunology antibodies. Regeneron will receive a $1 billion upfront payment and up to $7 billion in potential milestones, with cost
EQUITY | Oct 01, 2026, 05:08 AM UTC
H
Regeneron, Sanofi Expand Alliance With $1B Upfront, Up To $7B Milestones
Regeneron Pharmaceuticals (REGN) has expanded its antibody collaboration with Sanofi, adding four long-acting immunology antibodies. Regeneron will receive $1 billion upfront and could receive up to $7 billion in milesto
EQUITY | Oct 01, 2026, 05:01 AM UTC
M
Regeneron drug halves muscle loss with Novo's semaglutide in trial
An experimental weight-loss drug developed by Regeneron (REGN), when combined with Novo Nordisk's (NOVO_B) semaglutide, reduced muscle mass loss by 50% compared to semaglutide alone in a study of obese patients, accordin
EQUITY | Sep 30, 2026, 10:30 PM UTC
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
Regeneron Pharma Price Target Maintained With a $737.00/Share by RBC Capital
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 12:45 PM UTC
L
RBC Capital reiterates Sector Perform rating on Regeneron Pharmaceuticals, $737 price target
RBC Capital reiterated their Sector Perform rating on Regeneron Pharmaceuticals's stock with a price target of $737.00.The price target implies a downside of 2.0% from the Sep 28 close of $752.25.Key takeaways from the a
EQUITY | Sep 29, 2026, 12:36 PM UTC
L
US drugmakers turn to China for licensing deals
Merck NYSE:MRK on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.
GEOPOLITICS | Sep 28, 2026, 02:31 PM UTC
L
Weekly Recap: EYLEA, DUPIXENT and LIBTAYO growth and Q3 2026 results
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) heads into its Oct. 30 premarket Q3 2026 report after strong growth driven by EYLEA HD, DUPIXENT and LIBTAYO, highlighting upcoming C5, hem—onc and Factor XI data readouts as
EARNINGS | Sep 28, 2026, 11:05 AM UTC
H
Regeneron Pharmaceuticals, Inc. (REGN) Sets Q3 Results Date
Regeneron will report third quarter 2026 financial and operating results on Oct 30, 2026, before U.S. markets open, and host a call at 8:30 AM ET.Material DetailsContext by AI AnalystThis is a routine scheduling notice a
EARNINGS | Sep 24, 2026, 08:11 PM UTC
L
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, b
NEWS | Sep 24, 2026, 08:11 PM UTC
M
Regeneron to report Q3 2026 results Oct. 30
Regeneron said it will report third-quarter 2026 financial and operating results and host a conference call and webcast on Oct. 30, 2026.
EQUITY | Sep 24, 2026, 08:05 PM UTC
L
RBC says AI weakness appears to be fueling biotech rally
RBC SAYS AI WEAKNESS APPEARS TO BE FUELING BIOTECH RALLYWeakness in artificial intelligence-related stocks may be helping fuel a biotech rally as investors shift money from volatile technology shares into healthcare stoc
EQUITY | Sep 23, 2026, 01:15 PM UTC
L
REGN: Strong growth in Dupixent and EYLEA HD, with new launches and pipeline assets driving future momentum
Dupixent continues to drive growth with strong performance across multiple indications and high adherence, while new pipeline assets and strategic collaborations aim to sustain leadership in immunology. Cemdisiran is poi
NEWS | Sep 14, 2026, 06:49 PM UTC
L
HSBC raises Regeneron Pharma price target to $920 from $800
HSBC maintained Regeneron Pharma at Buy and raised its price target to $920.00 per share from $800.00, according to TradingView News ratings actions reported by Benzinga.
EQUITY | Sep 10, 2026, 01:48 PM UTC
L
Sanofi and Regeneron eye extending Dupixent US patent to 2033
Market talk says Sanofi and Regeneron could extend Dupixent’s U.S. patent by two years to 2033, with RBC Capital Markets citing a 70% chance in a research note.
EQUITY | Sep 09, 2026, 02:49 PM UTC
L
RBC starts EU pharma coverage with Outperform ratings for AstraZeneca, Roche
RBC Capital Markets launched EU pharma coverage: Outperform for AstraZeneca and Roche, and Sector Perform for Sanofi, Novartis and GSK.
EQUITY | Sep 09, 2026, 02:43 PM UTC
H
REGN: Record sales, pipeline milestones, and strategic collaborations drive robust growth outlook
Strong financial results were driven by record sales of key products and enhanced profit recognition from collaborations. The pipeline is advancing with pivotal data and regulatory milestones expected, while commercial e
EARNINGS | Sep 09, 2026, 02:27 PM UTC
L
REGN: Record sales, pipeline catalysts, and strategic collaborations drive robust growth and future innovation
Strong financial growth was driven by record sales in key franchises and full profit recognition from collaborations. Pipeline catalysts, including new launches and pivotal data, are expected in 2026, while strategic col
EQUITY | Sep 09, 2026, 01:48 PM UTC
L
REGN - REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Infor
REGN - REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses
EQUITY | Aug 20, 2026, 02:26 AM UTC
L
Regeneron (REGN) announces investor conference presentation schedule
Regeneron (REGN) announces investor conference presentations, with no additional details on timing, content, or disclosures provided in the feed.
EQUITY | Aug 19, 2026, 08:05 PM UTC
M
FDA approves pasatru (garetosmab-grts) for FOP adults
Regeneron Pharmaceuticals (REGN) says the FDA approves pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva.
REGULATION | Aug 19, 2026, 05:59 PM UTC
H
FDA approval for REGN Pasatru™ in adult FOP patients
Regeneron (REGN) says Pasatru™ (garetosmab-grts) is the first and only FDA-approved treatment shown to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in a placebo-controlled adult FOP trial.
EQUITY | Aug 19, 2026, 05:58 PM UTC
M
U.S.-China biotech rivalry drives pharma dealmaking, policy scrutiny
China has pulled ahead of the United States in two of six domains in a June Cure Innovation Index survey, while U.S. agencies and lawmakers move to screen biotech ties and licensing deals continue.
GEOPOLITICS | Aug 13, 2026, 02:41 AM UTC
H
Regeneron Stock Drops 9%
Regeneron stock falls after clinical trials
EQUITY | Aug 04, 2026, 10:36 AM UTC
L
Regeneron Awards $150,000 Prize
Regeneron awards innovation prize
EQUITY | Jul 31, 2026, 11:00 AM UTC
H
Regeneron Q2 EPS $14.29
Regeneron beats Q2 EPS estimate
EARNINGS | Jul 30, 2026, 11:52 AM UTC
H
REGN Regeneron RESULTS: Q2, Q2 ADJ EPS $14.29 vs. EST $10.3, Q2 REV $4.291B vs. EST $3.816B, Q2 EPS $12.23, Regeneron Earnings Notes:, Outlo
REGN Regeneron RESULTS: Q2, Q2 ADJ EPS $14.29 vs. EST $10.3, Q2 REV $4.291B vs. EST $3.816B, Q2 EPS $12.23, Regeneron Earnings Notes:, Outlook FY CAPEX $1,030-1.100B, Q2 dupixent global net sales rise 38% to $6B, Q2 eyle
EARNINGS | Jul 30, 2026, 10:31 AM UTC
L
REGN - Regeneron Reports Second Quarter 2026 Financial and Operating Results
REGN - Regeneron Reports Second Quarter 2026 Financial and Operating Results
EQUITY | Jul 30, 2026, 10:30 AM UTC
H
Implied EPS movers for tomorrow AM: MA +/-2.8%, VLO +/-3.9%, AEP +/-4.6%, BMY +/-3.7%, ICE +/-3.4%, REGN +/-4.3%, TT +/-7.2%, EXC +/-4.3%, P
Implied EPS movers for tomorrow AM: MA +/-2.8%, VLO +/-3.9%, AEP +/-4.6%, BMY +/-3.7%, ICE +/-3.4%, REGN +/-4.3%, TT +/-7.2%, EXC +/-4.3%, PWR +/-11.7%, ALNY +/-9.9%, XEL +/-6.3%, MO +/-3.3%, SO +/-2.0%, YUM +/-6.0%, CI
EARNINGS | Jul 29, 2026, 06:05 PM UTC
H
REGN Earnings pre-market tomorrow: qtr EPS est $10.26 (high $12.33/low $7.64), 30-day avg EPS revision -8.4% (0 analyst(s) revised up, 14 do
REGN Earnings pre-market tomorrow: qtr EPS est $10.26 (high $12.33/low $7.64), 30-day avg EPS revision -8.4% (0 analyst(s) revised up, 14 down), qtr revs est $3.82B; FY EPS est $45.74, FY revs est $15.91B; short interest
EARNINGS | Jul 29, 2026, 05:07 PM UTC
L
REGN seeing little to no movement post OTLK jumping 24% on FDA approval of Lytenava for wet AMD thus far
REGN seeing little to no movement post OTLK jumping 24% on FDA approval of Lytenava for wet AMD thus far
REGULATION | Jul 24, 2026, 06:52 PM UTC
L
BDX REGN SJM session highs
BDX REGN SJM session highs
EQUITY | Jul 14, 2026, 05:13 PM UTC
H
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
() -- Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday. As of July 6, the NYSE Arca Pharmaceutical Index
RATES | Jul 08, 2026, 03:11 PM UTC
H
Regeneron price target lowered to $769 from $778 at Truist
Truist lowered the firm's price target on Regeneron to $769 from $778 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a t
EQUITY | Jul 07, 2026, 01:13 PM UTC
H
Regeneron price target lowered to $696 from $707 at RBC Capital
RBC Capital lowered the firm's price target on Regeneron to $696 from $707 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has pick
RATES | Jul 07, 2026, 11:27 AM UTC
L
Regeneron price target lowered to $800 from $990 at HSBC
HSBC lowered the firm's price target on Regeneron to $800 from $990 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperforman
EQUITY | Jul 06, 2026, 02:25 PM UTC
H
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
The U.S. Food and Drug Administration (FDA) on Monday named seven companies selected for its FDA PreCheck Pilot Program. The initiative aims at strengthening domestic pharmaceutical manufacturing, improving the resilienc
MACRO | Jun 30, 2026, 02:17 PM UTC
M
'Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities' - CNBC
'Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities' - CNBC
REGULATION | Jun 29, 2026, 06:55 PM UTC